Stoke Therapeutics (STOK) Non Operating Income (2019 - 2026)
Stoke Therapeutics' quarterly Non Operating Income came in at $3.4 million in Q1 2026, up 17.07% year-on-year from $2.9 million in Q1 2025, and down 74.97% quarter-over-quarter from $13.6 million in Q4 2025.
Stoke Therapeutics has reported Non Operating Income for 8 years, with the latest figure at $3.4 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 17.07% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $24.3 million (up 54.7% YoY), and the FY2025 full-year result was $13.7 million, up 10.6% from the prior year.
- Non Operating Income for Q1 2026 stood at $3.4 million, down from $13.6 million in the prior quarter.
- The five-year high for Non Operating Income was $13.6 million in Q4 2025, with the low at -$428000.0 in Q1 2024.
- Average Non Operating Income over 5 years is $2.9 million, with a median of $2.6 million recorded in 2023.
- Peak annual rise in Non Operating Income reached 31214.63% in 2024, while the deepest fall reached 1119.05% in 2024.
- Tracing STOK's Non Operating Income over 5 years: stood at $3.2 million in 2022, then sank by 98.7% to $41000.0 in 2023, then soared by 31214.63% to $12.8 million in 2024, then increased by 6.29% to $13.6 million in 2025, then tumbled by 74.97% to $3.4 million in 2026.
- The last three Non Operating Income figures came in at $3.4 million (Q1 2026), $13.6 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | 3.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.42 Mn |
| Dec 31, 2025 | 13.65 Mn |
| Sep 30, 2025 | 3.47 Mn |
| Jun 30, 2025 | 3.82 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Dec 31, 2024 | 12.84 Mn |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Mar 31, 2024 | -428,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 2.69 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Mar 31, 2023 | 42,000.00 |
| Dec 31, 2022 | 3.16 Mn |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 586,000.00 |
| Mar 31, 2022 | 146,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 86,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 34,000.00 |
| Dec 31, 2020 | 28,000.00 |
| Sep 30, 2020 | 27,000.00 |
| Jun 30, 2020 | 53,000.00 |
| Mar 31, 2020 | 22,000.00 |
| Dec 31, 2019 | 908,000.00 |
| Sep 30, 2019 | 2,000.00 |
| Jun 30, 2019 | 626,000.00 |
| Mar 31, 2019 | 580,000.00 |